0001493152-22-023342.txt : 20220817 0001493152-22-023342.hdr.sgml : 20220817 20220817170019 ACCESSION NUMBER: 0001493152-22-023342 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220608 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40023 FILM NUMBER: 221174947 BUSINESS ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-K/A 1 form8-ka.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report:

(Date of earliest event reported)

June 8, 2022

GT Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of Incorporation)

1-40023

94-1620407

(Commission

File Number)

(IRS Employer

Identification No.)

8000 Marina Blvd., Suite 100

Brisbane, CA 94005

(Address of Principal Executive Offices and zip code)

(800) 304-9888

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol(s)		Name of each Exchange on which registered
Common stock, $0.001 par value		GTBP		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”) is being filed by the Registrant for the purpose of amending Item 5.07 Submission of Matters to a Vote of Security Holders of that certain Current Report on Form 8-K originally filed by the Registrant with the Commission on June 14, 2022 (the “Original Form 8-K”), to provide additional disclosure regarding the tabulation of votes at the annual meeting of the Registrant’s stockholders held on June 8, 2022 (the “Annual Meeting”), on the proposal to amend the Registrant’s restated certificate of incorporation to reduce the number of authorized shares of the Registrant’s common stock from 750,000,000 to 250,000,000 (“Proposal 4”).

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Registrant disclosed in the Original Form 8-K that the following summarized the vote results for Proposal 4:

4. Proposal to amend the Registrant’s restated certificate of incorporation to decrease the authorized number of shares of the Registrant’s common stock from 750,000,000 to 250,000,000.

For		Against		Abstain
19,568,632		215,253		141,506

The information reported by the Registrant in the Original Form 8-K was taken from the Final Report and Certification of the Inspector of Election for the Annual Meeting reporting the tabulation of proxies and votes by the Inspector of Election for Proposal 4 as follows:

Proxies were solicited on behalf of the Board of Directors of the Company and a vote was taken for the approval, of an amendment to the restated certificate of incorporation to decrease the authorized number of shares of the common stock from 750,000,000 to 250,000,000. The proxies and votes were delivered to and tabulated by me as Inspector of Election, and the results of the tabulation were as follows:

Votes For		Votes Against		Votes Abstained
19,568,632		215,253		141,506

While the definitive proxy statement for the Annual Meeting, filed with the Commission on April 29, 2022, indicated that Proposal 4 was a non-routine matter for which broker discretionary voting was not allowed, Proposal 4 was, in fact, a routine matter for which broker discretionary voting was allowed under applicable regulations. As a result, the Final Report and Certification of the Inspector of Election for the Annual Meeting included discretionary votes by brokers or other nominees holding shares for Beneficial Owners in the tabulation of proxies and votes on Proposal 4, resulting in the foregoing tabulation.

In light of the determination that Proposal 4 was, in fact, a routine matter for which broker discretionary voting was permitted, and the subsequent filing of a certificate of amendment to the Registrant’s restated certificate of incorporation to reduce the number of authorized shares of the Registrant’s common stock from 750,000,000 to 250,000,000, the Registrant intends to hold a special meeting of its stockholders to ratify the inclusion of discretionary votes by brokers or other nominees holding shares for beneficial owners in the tabulation of votes on Proposal 4.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		GT BIOPHARMA, INC.

Date:	August 17, 2022	By:	/s/ Manu Ohri
			Manu Ohri
			Chief Financial Officer and Secretary

3

EX-101.SCH 2 gtbp-20220608.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 gtbp-20220608_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 gtbp-20220608_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 08, 2022
Cover [Abstract]
Document Type	8-K/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Document Period End Date	Jun. 08, 2022
Entity File Number	1-40023
Entity Registrant Name	GT Biopharma, Inc.
Entity Central Index Key	0000109657
Entity Tax Identification Number	94-1620407
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Marina Blvd.
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	(800)
Local Phone Number	304-9888
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	GTBP
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 form8-ka_htm.xml IDEA: XBRL DOCUMENT 0000109657 2022-06-08 2022-06-08 iso4217:USD shares iso4217:USD shares 0000109657 true 8-K/A Amendment No. 1 2022-06-08 GT Biopharma, Inc. DE 1-40023 94-1620407 8000 Marina Blvd. Suite 100 Brisbane CA 94005 (800) 304-9888 false false false false Common stock, $0.001 par value GTBP NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gtbiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-ka.htm gtbp-20220608.xsd gtbp-20220608_lab.xml gtbp-20220608_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-ka.htm" ] }, "labelLink": { "local": [ "gtbp-20220608_lab.xml" ] }, "presentationLink": { "local": [ "gtbp-20220608_pre.xml" ] }, "schema": { "local": [ "gtbp-20220608.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GTBP", "nsuri": "http://gtbiopharma.com/20220608", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-ka.htm", "contextRef": "From2022-06-08to2022-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://gtbiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-ka.htm", "contextRef": "From2022-06-08to2022-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 13 0001493152-22-023342-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-023342-xbrl.zip M4$L#!!0 ( B($56;4'7]&A8 '.D , 9F]R;3@M:V$N:'1M[3UK M5^),TM\]Q__0R[[/'N!^?5O5><" M@:#H!$<<9_<9QZ2[Z])5U575U9W#_XT'*GF@ALET[7,LG11BA&JRKC"M^SEF M6YU$/O:_XO;68<^"=M!6,S_'>I8U+*12H]$H.!II:H4US3E/+:\I,/2NF]Q[#PVGA=Q@O:YM&G(%"^OVH<3YM M;H6WGS9-68:DF1W=&$@6S"&.E$L(8D+!AJ=M([J?JNNU6;Z ML"YHR!C0 +\OZH!$R=EX(XAJ35-H>,S.KD3X$]:V-_-[3UGW-S,N*4! MU13XSSI6I>Z=9=CT&2/M(J2%G<> MQ $!@W6XJ"OLP>NG,'.H2I,"T72-\I=L7$"9I08J _^-*0K5N&K@K]#PTA[ M6+(C]6.K@>;CV- '*"H)81>,EJ5/_QTC&E -H"@KA I#K#B5AL-4 $0T4 .B M$BNBK(3"206H1;!@^Z@!RS$UG19H8@LF7SL!/N$+8J''[2>HW3#A*4MR;"HQ M][4%%N)SS&2#H4H=J^"""@[N@#-UV_"@03,^]0678L*41RGVK)?7C7)F^T_] MYTS!-QU&#<))H:$+4[EV%IR8^"ZT(?!75Q:Q ._ L"J218M3$KR1 MIN\6NL%,+NGDO9E'*X" ]]!E:9#/ML8<)H/6+7!S0"73-FC15<\"M/$&\UX% M0>!H2\9W='TI")<)O-&+84QMR@(8E^N$)*E&S.OG\^#>1S#1IT! M6J&:/F#:4V"?YLL\W+"!O??6:P:MDH3 M=:G+U]39]6+$%*N'L(5_8H$7;=T QB0L?5@@1ZHD]TD68)JZRI0#XKYLZY:E M#[SWZ61NV@))2ICL%ZR.Z:$U)1V9[/X]@UXJ@-\[FH)UC6\.)6UVZ$1'&C 5 MEOTG!I^=%@#@#F_#PFU@V)+@0Q:(HMMM6-R"<'A3A.9 O&[(<'8]R<2%5VV,8[#I,N=[*7[+P]:IY\O^@#6K\;.,[" MBQ7SB;-4:3YP?/V5;/WB&>FTPM8WJ!#W; *FX;_CD\ E2"(H:9%Z - M(0:GARI_S"@LQ%F8RG4IV$Q;L0Z*YA>@_3F7HLZSA%4GAQB^ K7RW_)[/_6: MV9=>O (YVWN?8VQL%12 -(!^/46:3$"JJ!;F>P00BQ6_V!J(83Y.<-0_[XR\ M2#.$%<@$= M4,.GGD@F,8=4QKTUA3"8*,LDX*V";V&\IF_QA\++UUCS=P,"#Y*E&T,77M." MU;7L5)F4=66)_+.^>O1UOUG?O[B/P@/ HB#()C355I M!,[#X[[ YE@K1TTXG>!N&T2W>M0@7R"",Q7FQ'B@-P&F/*4>;XZ\<*?&DMHJ M!6BJ"L]E7O\GQ/CO0TE1O-^?3=G,EIV_$R?KJBH-34#(^Y>S27QH&<\'\$ - MB\F2ZO$+O ]OR_G04IX_7BCO%Y>O;$";CYE*0?3;U A776T/8K1=_2ROJ)$M M75.8L6(ZD14$,?/H4F4I4;/%$Z3H1PYA>"; \)8TKKFU(#+7PL>XS[H_ZY>C M!Z.KYB+C_A($8L7];"*]*PI98:&::&8V"&<:_&6\9<'WM3>[CY[^"^Q:V)@K M[(Q$ZH^W%UTUSJ/-)&>GK \&S,1Z[?="$AHRXJC/[%H:O5V91J[_K'$]71O6 M4A2#FJ;[XYQI-!V^>M>S>X9XU3H]U?*>4$0MKF5X9=8C8F28O211\UV^_M0V1G9:[49,T!S]6+"^K25C0D>,P M>NJZ:4GJ+1LN3WM\WS<;BGY#AR_/>BPA)@ 3[AG6P:C(; M2BJICJEL6^R!DJL.K(\PI*0IY!<; CL5^DK9C,U?S;P$ "IYR:#2<@&VZ^JW M[*!+I?LH\M:S\&".8='ZM$1F%TV*5_=RKD/<6._IVJ-)B]RM=3SZ_K4\:D5A M1N9AQHH9(9O8S^?S[TGEIOL)__EW7DSO'8#V652E0R2<:)SR. %55&W,J1$) M9G(EO8NP\&_3RD&6HXUY>F, -FV5HV?E'I7[,!L]2J3AT-"'!H.U#!@[)FVJ MZB/".@1?'L.0))\X(QVFXA0Q$^;+HII"%2SU,=G 5BU8R77;5"?$A/C"[$QX M3[>#W@:\)2]7/+/'PDO0P=I.N$7F/705(&,GS,$SC.K--1>G1,3-OS>)O+(F MSG(=M]1].H2DF NMMGW6#,P;]XIKW&\,9H&X8I[(UMSXUPRW\.J>DB^?'O<: M1YU(:DK:NJY22>M(*IX#G]K^4)10AO;WLMF#I^I(EB=47CP5O\M[ER '+3E M%AG.U 5B#0/)BCE7]:U@/2"6 >ZD]TCYN$'$C)"$AI]FJ7Z]_/!O,/+I38!H M!M\(9D2KT5X$V-15)H/(:-T+6+%@V5+#U7G4F'S1^O>7U%+6JLZ+^&RR+D^I M<3 ;N#0M*G(Z*R72XD[[TXPZ!VIZ?67."DF_\2?RH=,?.CV?!:D;%)=#/(#/ MSWB@?VE 0+XL&/LV.KO^>G-[SW;S:]7MY7AMLHX#50EYAJS5%NYT5DFLKNY. MVX\%_$/9?64OA2M[S31M:CRI\ITO_[F>(8!<>G*Y/]9,=?[K"EJX8UL#A'\+);<(V55,LU'3: [3SZ1G+Q +ER M/T[^3T@*0IH,)8,\2.KBU6Z/^4CK<86KX8YNA\_#[4]+;+5&D_%N M!-,0@(O323NR4R$4H"X>" G#"0Q^ MS[5GEY*I2#])$_6"7$A&GUKD_+R\PEQ]>,O1HUK3%(QO8&[:$R+CUB<"[<,* M0_F1%O2,9[8F&5:!$ B1$*\NZ1KZR.IAG 0X3/!PF$([3'..ACF;&D+.<[#G M=C2)GZ=QPBNQG1!#>H?=CQ",M;#CI^1Z)X ?=?U=]E==3FYO MS;'R\9(UK]L)[U1V^H3K_76^<_JE5Q^H/7FMV8%'$%LY,?"6%663=+JSO;5< M2[&LQ-%Y$E1YMZYA1MM[H-!4A6 9%%K3>>ALFY2W JS=4@>\#YSQ<-JYPQ2E MA<-2)URP1PQ@HTAK@"^\,N@#,Z$CV E)DW$#19+YS=F(*M[&KDB&8CJ%#LJR MP#VS(_F!^ZPY2!)?U#9@HC9(IEYR3< SKN$,!&*AH5IV^.:OX?Q;A2$H#LCI M VCYT\9D*J#LL)U[U(LR\$@\/G?L8Y<76$[37+-IK?FT5Q#&8KYJ+J^U6,Z>C?S+K#%H%(_T:9@1 &;(>?E['&8=\R%69U= M]WT>&U/BR/].,RW\Q%?@9L9$.N*K&=UBYF)U/%0E#:^GGN"5[MX2-PTX:ZB=>%@/.)PV"G0U:L M671 !6JNK$P9='M7,(<82^<87W,(\<%CF)0Q9:=(,&I8\=6DFWU8')^ M07_WZR .@=M;(:!DGCYU""4=B$O)7DZ("P+_#T&(,[_NN(36/4*R'I%KCO\W M=0E9H_E$7=_>0F5/OD3;DZ]F>.=8(23#ZZS?V$3^$5(<%Z 55%7/Q#F)/E3U M!2/IV.S@X073'@!!W K@"[1_:%=LU3+Y.C+5X<)KIH8^I&%E4K+)[:UZY$N& M0F4(>]S,TLQ2,5T_ HM&"*SMK>-$@ MA-=5U=T&\6+O8)#GHH;_6HPY(=X;,_[:M">I'4^$CG3)4/"7"C/X//O>5-G; MO0>1D!RG?$9071'C1Z$?)#7.HWG-(!1?D.U8.XT[HW#5=)U8P/KG_= MU_=D\#:2%,=QO>DQ/(J BQ6OS6/\2B=<(?&SW/AQ#SJSBQ/T)./NKL^2+9/2 MT& J$?>=;8=I79'BY/YF_$;T)R2\+#T!*@LC T(#GA'F@)UJ]K:A]^$!9A8- MRG=2C DNWNC'8G\L0))P::5*?&YL!$TZDFS!.DU<"&0E -M;,Q#>S'OPVUMS+KQS\P_@LL .QV-W:#&)?_4X M_X(PA9>X,\1SK8X/A0".J 8SSTNMKD8:=G,CE-#08-9K@A=33L==JAW\W-0N ML$;GD88_5/(C,GB3I-2T[2T5'21/(A4*^L&_.\T=\T65?;E:S>KM$(% '\5W MHK>W3+MM\@(AR[\,":**^3SQ0HP1Z;8DOUQIV;YD&*CGQ"'QQ9P UDOR#3#4 M4""6?T9#4L$23K=\\6L:@?U=1%Q"Z>#C<:O@;:E%81G:OF4 ;CQB&D*LP3O. MH3]>SR8>D"O^)4:S@(#+\1X/SR4PNVMO@ M(UZ97_ %YNAH:=9.+DNMZT;U->ZQW+BI><['J:,GQOM\*X107J+SI\T,'C;Y MWL(3AY,6O $\6*'8ZH3(DFWR>(F9;MH>E_PV)290Z:1QT2=P4[GMB1/(\0#% M;0%+/+4U3*OB>%-_9EWK\ZO+S?N^V&#U\5:X\N3M?9KB-1&%.VR'"QX>]-?^@E<3)K;C.^B!'#.;B+2F4AQ M7CN+]];,XK>M'E'2CI]1+FR /2[977#$'.32>][WGM\\VD>3QYF[ZF4Q?YJ. M0U9,F2D'_0M)L\E5SV!X:.+OU)IWX<9\(/H21%'Z'=0<%?@0_S<\61^(1HUH MN<=HQ\'MV+]7P?ENC\&W79I8=&5)QN1U+]19\X2LDJ_/S.3KSR73^LC/1Y"? MS[PT/_]*6>C(':W0CRNFVKHR0:5)]:R!6@S*89-:'M_&ROB U"K\'W="_NB. MWY["O^+BT,_[T2_CXWM%..OV2U][MZF2,KX7K\S1M_MZV1Z6SR;EFJ8KICE6 MM<;IK:7\]_3G(-,^OF(_;DH_?CUH5]6;6O^;T;J^;)W)N?[UU9'X2[JY'U1+ MS.I?'G6$^\%DORF?=DH_4]*5VC[9I_GZKXONK]TO_;YZH=V6]S)I@XDW9]>M MEGD[N7>W17J5S?M7(?=&_-.K9XQ\7W[]; MUJ[TZ[XW_)&^O,^>W]O=U$CX;Y4-O]2[GS\[+/E_4$L#!!0 ( B($56_ M_W+Z, , +0+ 1 9W1B<"TR,#(R,#8P."YXPOT5W\/(;@BF 8U M<,E]V&)]?@J^H1#7P#5F6"#%Q2EX0#0V%GY%*!:@R<.(8H6U(XU4 ^6"6_8 MA'OH/F 6<''?;1I@=A)?(C:6C^A#\]&[K?XN_SBYP<_#T>/%1^\N1)?3 M+R\E,OU5:08WG>[WT'GZ\C4-69?^$(<(Z,M@LF&9^K+RQJ4"%P.[Z#BN_=1I M]Q*0$T_07+ID&[>'))XI:R_9@2=,*L3\)7R@ M9H1%<-E.G4M0LA%:2:$DAP9X!2>Q7QCPD:T=&E\LYL!8P@%"T0S<1])+1#/' M$E@*M0[4QE405-,(RXW0U+5$N+Z[N)UA!\HC/!HB$2+3E@G0J3@G>K@H#C%3 M5UR$E[B/8JIS>8D1)7V" PLH) 98F3Z3$?+QZX)YOR+&N&YK/5N9Q=BBB.B^ MU88W=7/!-<$IOM.9 [/0 [55WOCM)M?O@@5(T+#2I1'2LHE4@/N$D21>-CPN M@&948E.>7B:4NKT*7I"()0YNV%FRC@26FI<4T-:&C)A!MI!\1/V8'L:9I[*1 MDAGR@YH?73X@7=P'R6#53 LT+$G,TV9EMJ' _8:E3S."^0W]U*45=(OD$".] M8["2DU\]C2QP+H&$OZ:R-OA:A$=8**+[=&&ZT]2),O3;A3# Q)$6L/]%R11Y MAY:L*9C^QUK;1G^QR&Q&[/F09/O50:KKZ2%)S$_@L"1RWA%);'F<-\67V^!FD;30OD&W//([@V[D MV)@JF5N.3F'QE_ 7.20R!R6Q=)V!$K:1,*(.=%Q8=+>G\QHSVD@C+%+RS7&W,?^9[W<1.3Z]!/-_/S;L$5VP'GQ3"]3M5$TO_P!02P,$% M @ "(@154Y(345#N^ Q]?W3\ M_0J-QP/J_49HS/C7^WE=[V.>/V=GD\GKZ^L192_XE?&G["ABFV$5+G*<;[.Z MMH^[C]6?,OQ3FM"G,_G7"F<$B>-%L[-=EIR/Y'ZKW;Z>'#&^GDP_?CR>_//7 MZT7T2#9XG%!YW"(R4E&R%EO<\>GIZ:0H55)#N5OQ5.WC9*+LU#6+TJ1#WW"2 M)6=98>^:13@ONKUW-PA4R/^-E6PL-XV/I^.3XZ-=%H_4P2^.(&'Y_]" 9KSS)BQ9CM-WF6]& M.K=]0]YWQ ]Q[H^T&.?)^XYT(_+_8CLW+;_Y\-J/:RHW7HM/+8MDEXL)C,3* MI*RB8P0N]E!,#%7==>TL:M6;RM&<<;/M<&5+\RCGL95BDG$Q-3TG(_3 M\C"6X0^<;:R[K5K-+(5_I*LZOCPL8A> T9:,DXQM>43>U"M-M]!1JAQM4J&0 M2RI"QU\7HQ\+#?I=J?[S:7*HQ4%'BR70=D-HOA0U6EK0+G;5S393JI>;94%T MLL60WL=*@J3&<0=?B!W'[).Y-0B+DV?&N_!IRUQ38S.I MP]+4!,6(Q1B(1JE%I=@3$?_8BC-VPM-]+Q2&TC47@%4=#4T6%!UV;R @M=PO M(TN.:9;( :P7$E/J_'0#,&N<>FBZH#@!S,&G)+7>+RF+1Y*F\GX IOT#BDWL MFA;8L,Z+J0R*&- >R$P1@:J0<+"Y?)&K<[%,&MC8AMXG/(;M+GYJ<; (Z0X' M4E2$(1GGB:3&;8@>A@RE:WH JSHWFBPH8NS>0%9*.2KT_B&YI/$@1&J='T T MFW8\*E& <+2=]:$AU#[!N$JR"*>EERNQ+>MHGD7K&A#0K@Z)(0P*%,@="$L9 MH)@I0KP"\R^"^3!<&DH_L!A6[:C4L@!!T;WU82+U7B"9;3EON89G'%CJ[*9L MC]GZ_BR@"P*4'G/&7=M2W@+%TPQT2?,DW\OGZ6ZVFQ7AEL:9$E=L0.84$WIY M$"P IG0&2AF2.E0*O?2\NDM <_D0(]@<7>:6 +O)-@5M34 D6(T!-!RTQ3.E M7HB8B9&)XW1.8[+[A>S!=ADZMTP -MM0:** J+ [ ["HQ*A0(R'W L8=3S:8 M[Q=)U#-5F$*W:$!&VVSHJH#@ *P!=%1JM)C/?,XD2[R;QP+4Y"$IGP?OH034 MNX6EQW:;&4 <$#K=#@&"1!!J1_D$:4XCQI]9XW&'&=N* 7 _8S&\0NF)<@O5 MH":TT>H,"0BP(3X!S%JA'\IG4A"3[_$4%2!9@Q?B+N)8'*BL^N08;+]5 MZY:N#KMMIBS"@$B"W0'\5,H/Z@.2,>B6A@+-] U-G?J'9CH4FFG0T$S? \WR ME04"S;0]G@THOR)A6K< < M9.'A8GCK@T4&R/6,#/&)2;&PNN5WG+TD-(*7S)#<"S" :2LUFC8\=.P&^_BI M%\0JSNM84R[*>[\D2N9GE&F;M \QI28\2-K&>@>74NT3B3N6Y3C]=_+<>2)N M%WO!PVK8"DE+&1XJ-GM]P)0Q2 3Y.+&N<)4W-*RODFGE[EX!MM@ZO +<* P" M ILC\Q7@\NI)*7+=S9)13C P(K2+G76RQ53=QXVR,+K8-&3TV04?D# E+CJ:!TSIO5[(4*'S=#5>9IC([,-WH\S9S*[; MJ2=R51!$[^INC&E:E3ONS=]XDHL]S]AFLZ7571[;4+7OXJ33YY@6ZML(E= P 85#:8B"!1 6SH'!R%2 M2L<0W'$B(22B(XJ7 &5B(7[[\&"=[;O$KJ#H-ZS@@)5!0-)K3X=%!(RC1@0J M0U 1XQ>;>99M"7\3/)803PB!Y@&0#'V(.$$F>Z$J WVRM2#15LR/^^/I:IGD MJ>WDTI0XFY, <_6,I)4'P09@2F>A*$/L 1U/_[;Z#JDHQ]U_PY8.DI)(BI?7Q M0L)AREKW+P+6WA8!ZYY%P#K$1GV^*_5^)#Y96 CIG.2V[;-9) M+6VB(!CI?1@,#3-IX%2&J5R&=> AU:7K2^GE QB_D33]A;)7NB X8Y3$Y;44VYVB M;KW;)V9Z;+ TQ"'PZ(P,&C_)**3"JBMA7DCZQM(MS3$OWB7GMI$) MT+DE![#9)D83!42*W1E 2"U&I=K/"]IE]HAZD57^[A#80$CN^'7M3M/:6]M6 M;4#,=!J$WN&N2%?<(XK;V![(;GKERJ[3.MO4]JT M 2'4:1!\?[*.D:EBL&+*6\H8/A-+K37K>$I<4[E/'&-8-'/'U)* \+#YZL@@ MPY'2>F%AL<%I^GF;)91D\$2DJ=RR8+789J$E"8@%FR^ A4**E-8+"Y<;PM=B M>ON9L]?\LUJRO(,@ M( ),5U"*O$*("J67_O^,Z1/?/N?1_HZSB!#YE%56CU9]U]\&1KMEYDU-:M,T M*#0@SM[B%R#P4 5JU/&A,6/YO)@G'QJ7V=Q8]+1XQ.( WF[S3,Z@PAA\%;PS MR/'MA0$-T&XR=$0$A-X F] -AR(2%:$?4!F,&M&>SL^R0Q9 $G_>WY,'PN5[ M!TNRRS^+'3UUG&$,B'5]]C:X.?K)7&]@$!"^U2UTJI>A9@5H)9\1JZI O\M* M4%&+[??+FYNNQ2>Q66T2?ZUP1L26_P)02P,$% @ "(@156;1$)A9!P MVU< !4 !G=&)P+3(P,C(P-C X7W!R92YX;6S-G%U3VS@4AN]W9O^#-WL= M0L*V6RAL!U+2R90"2VB[NS<=Q582#;*4D622_/N5[#C-AR4?;GS@ H+SZN-] MCBW[V)+//RQ3'CU3I9D4%ZWNT7$KHB*6"1/3B];74?MRU!\.6Y$V1"2$2T$O M6D*V/OSUZR^1_3G_K=V.!HSRY"SZ*./V4$SD^^B6I/0L^D0%5<1(]3[Z1GCF MML@!XU1%?9G..374?E$T?!:].>J^&4?M-J#>;U0D4GU]&&[JG1DSUV>=SF*Q M.!+RF2RD>M)'L4QA%8X,,9G>U':\/%[_%,7/.1-/9^[7F&@:65Y"GRTUNVBY M=M?-+DZ.I)IV>L?'WMK)ORVE!\KE M6/&RC9-.V9U-S?9;%M!O]42S,YUW[T;&Q.1AKVTF\BK^Z1[ MM-1)JX2?$U22TPJ_WU'9%9SNV]JYG:M5M39:7JNJ*;"Y&YO[(:=(G1I[!Y% MD[(BU_X+.F>8[B(/?08[#\_\H8NQ]HH$INR)D[&E.?U_[":/4FG@5Z5)!YM MC=6=VE7L]VD[;IB=;A[KA6=.5&VHG8\8WP3Z(F2J8_. MFH3T='0;E&VB&9J7MOW$]6' R;0:YYX$R+.+ ;32#1;1CU3'BLT=EQJP.TH@ MWQXJWPIO#6,NCYT'.F6NOZXK[J1+W<;PN. I @1_@CE2!-TB1>!2B(SP!SJ7 MJ@;\KA+(^P],WE7>D##_G1%EJ.(K".D#,1#V&TS8'H=(O!\5$9HY/A#@AVH@ M\;>H%QX>CTC(1S/*N4ODB #MY55Z(/8_,;'[?;X"\-?/[OQN3RUP]EM%@/C? MO1;\!VZ1(G!/%9.)/:4K /L#,9#Z*29UCT-4WM2,'Y#S[L/7M(J =, MQX07/1K8;3J,NT(.18Z2<];:1,7^+R4*#'U+#$6.DH;66&P8>#]3:J54,8HN6;(' KGOO6C"!^*A"X_TU4(]($42AHEQPS:0T%]KUA*U&K$XOI! MXU +A8V2688-HM!^),MA8EVQ"2L>"=9#]Q:!LD=)*T%V44(P%+%4<[EUN[@O M,WL\KOHR"0[I-06AX4#)-U]@'24HETEB<>GUGQLF:#<4BDHY^!D17@ "-E\) M]M[+L/?@V%'RT%J;KP3[R>)]!>,10Y2BY: M8Q$3>'ZFN5/W2CZS8F94'?6#$E#TB"EJV"SJ#E^ZF$\D9,5ZO-87*^ ME]H0_A^;UUU)5NNAS!$3UY#1IF\P%G%W-RU\4XGV)%"^*+EJI9VFD;H(*TK\ MN^^N @H4)0&M,M,PSQOIGGW,I C>CSU40;FB9)(^4TT/O&XNL?8>^EM?@V>P MH0RK^S8:QOA=,6-[T)=IFHGU/1K/4S&/%(H7)?T+VFL8]4AR%C/#Q/2+O4)4 MC/!JSE4Z*&249,]OK&'"]XJZ2%-[V9W/XW*+#=3=9.(;>4-Z*'&47*_>*"[Y MH=8952_E7U$*&@64M ]JNNEQAL:9'?96W=[XT:V8\8PR!RHH:Y24SV>J8;:W M\E$1MV)OM$K'DON7AU0*H811$KR M88A[_2C&N^>! H6);.KM(,T)EPOXQD1 M4^J?O5"MA )&R?1"YM#&WBEH[)V^<.Q%R?A\II#8%G/#[1%U-^9L2OPKR8(% MP.ML,(D'K#:]?B]?\N/6,LD0S9:QIUEC!#DZ)+ R:( MB&U*M5G7YLG.ZTM! X"SAA)H&N7V_G?*^6*10Y(C/#CWV<.9>%I.:-^>>XJ4=(>*^$E#P MB \1PV:1YJ<9ZOK,GNE'8LBZAR'^OA)0_H@/%,-FT>;/J[X]\4QE^)GYGA!* M&W$J;*4U%,BCE'!^E6DFJ Z.+7M"*&3$.:^5UE @7Z=43>V@]DG)A9FMUW:& M8'L*0*$CSFP-6L6!O_RYCKQ8_Q8D7Z$&OYT $;O7)-9K-^+83:0HSN0B(_,T.9MH4D/]:6@44!)5Z&F<J!3JARTQ0>Z=)PA=%@.+0^*"^40B,H2), MYYT#7S=V@WM+;?&-^^7>Q&JW_ ]02P$"% ,4 " (B!%5FU!U_1H6 !S MI # @ $ 9F]R;3@M:V$N:'1M4$L! A0#% @ M"(@15;__'-D4$L! A0#% @ "(@15